RBC Capital upgraded Neumora Therapeutics (NMRA) to Outperform from Sector Perform with a price target of $7, up from $4. The company is evolving beyond neurology, which is not yet reflected in the shares, the analyst tells investors in a research note. The firm believes Neumora is well positioned with a competitive early asset in an NLRP3 class demonstrating “emerging promise across multiple large-market indications,” including obesity and cardiometabolic disease. Data in 2026 should better define the target’s potential and could have meaningful positive readthroughs to Neumora, contends RBC.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Issues Shares Following Loan Conversion Notice
- Neumora Therapeutics price target raised to $3 from $2 at Stifel
- LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO
- Neumora Therapeutics Reports Q3 2025 Progress and Financials
- Neumora Therapeutics, Inc.: Promising Growth and Innovation with Key Developments in Alzheimer’s Treatment